ReviewCurrent rheumatology reports2012
Uveitis in seronegative arthritis.
Review in Current rheumatology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 23 citations in OpenAlex.
- Uveitis in psoriatic arthritis: study of 406 patients in a single university center and literature review.RMD open · 2023Review
- Ankylosing spondylitis and glaucoma in European population: A Mendelian randomization study.Frontiers in immunology · 2023Article
- Acute Anterior Uveitis and Spondyloarthritis: More Than Meets the Eye.Current rheumatology reports · 2015Review
- Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept.Case reports in medicine · 2014Article
- Update on juvenile spondyloarthritis.Rheumatic diseases clinics of North America · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveitis is the most frequent extra-articular feature in seronegative arthritis and is part of the classification criteria for spondyloarthritis. Recent studies confirm a prevalence of up to one third of patients with spondyloarthritis and a relationship with HLA-B27 and disease duration. In recent forms of the disease, a relation with infectious episodes, inflammatory bowel disease, and cervical spine involvement has been reported. Many data argue for the implication of the IL23/IL17 pathway in uveitis, already obvious in spondyloarthritis. Studies with NSAIDs, DMARDs, and anti-TNF agents demonstrated the ability of these treatments to reduce the incidence of flares of uveitis in spondyloarthritis. Only a few data are available with other biologic agents. New onset of uveitis during anti-TNF therapy has been reported. The Il-17 blockade may be a new option for treating both uveitis and the underlying rheumatic condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.